Dubois A, Féral A, Pain J-B, Michot J, Fansi Ndengoue D, Benomar A, Clou E, Debrix I
Service pharmacie, CHU de l'hôpital Tenon, Sorbonne université, AP-HP, 4, rue de la Chine, 75020 Paris, France.
Service pharmacie, CHU de l'hôpital Tenon, Sorbonne université, AP-HP, 4, rue de la Chine, 75020 Paris, France.
Ann Pharm Fr. 2022 Jul;80(4):531-542. doi: 10.1016/j.pharma.2021.11.001. Epub 2021 Nov 5.
The aim of the study is to provide an overview of Drug-drug Interactions (DDIs) and adverse effects caused by drugs used in SARS-CoV-2 infection during the first epidemic wave.
We retrospectively analyzed patients treated by drugs used in SARS-CoV-2 infection (Azithromycin, Hydroxychloroquine and/or Lopinavir/ritonavir) between 15th March 2020 to 17th April 2020. A review of adverse events and DDI-risky drug association on medical record was conducted for each patient. Each adverse events was analyzed by the Centre régional de pharmacovigilance (CRPV) to assess causality of drugs used in SARS-CoV-2 infection.
A total of 312 precriptions were analyzed during the period, of which 110 prescriptions had 157 drug association at risk of DDIs; 26 adverse events were reported. Causality assessment by CRPV concluded that 10 (35,7 %) adverse effects were possibly related to SARS-CoV-2 drugs with only 2 (7,1 %) related to DDIs.
Despite risk of adverse drug reactions and DDIs related to drugs used in SARS-CoV-2 infection, few iatrogenics diseases were found.
本研究旨在概述第一波疫情期间用于治疗新型冠状病毒肺炎(SARS-CoV-2)感染的药物所引起的药物相互作用(DDIs)及不良反应。
我们回顾性分析了2020年3月15日至2020年4月17日期间使用治疗SARS-CoV-2感染药物(阿奇霉素、羟氯喹和/或洛匹那韦/利托那韦)治疗的患者。对每位患者的病历进行不良事件及药物相互作用风险药物关联审查。每个不良事件由地区药物警戒中心(CRPV)进行分析,以评估用于SARS-CoV-2感染药物的因果关系。
在此期间共分析了312份处方,其中110份处方有157种存在药物相互作用风险的药物关联;报告了26起不良事件。CRPV的因果关系评估得出结论,10起(35.7%)不良反应可能与SARS-CoV-2药物有关,只有2起(7.1%)与药物相互作用有关。
尽管用于SARS-CoV-2感染的药物存在药物不良反应及药物相互作用风险,但发现的医源性疾病较少。